



# Belgian Journal of Medical Oncology



Volume 9, Issue 1, February 2015

## Introduction

---

Dear colleagues,

Welcome to the first issue of the Belgian Journal of Medical Oncology (BJMO), 2015.

The **Review in Oncology** is about **isolated lung perfusion for lung metastases**: how it is done and what is the tolerability and efficacy. This specific experimental treatment from Antwerp University is a possible additional modality to the more conventional treatments for lung metastases, especially metastasectomy. From experience with other sites (e.g. limb perfusion and intrahepatic artery perfusion) we know that the high concentration of chemo attained can produce impressive, sometimes durable remissions, even in patients failing systemic therapies. There are always patients for whom it is possible to go a step further.

The second **Review in Oncology** from the EORTC headquarters deals with **health-related quality of life (HRQOL)** research in EORTC clinical trials. The EORTC is to be applauded for having developed standardised scales that are widely used in clinical trials and which have helped to estimate the value of novel therapies over the years.

The **Practice Guidelines** are about the management of **clear cell renal cell cancer** by the very active and dedicated BSMO task force. They sort the use of many different therapeutic agents, targeted and immunological. Also, in that disease, we are at the dawn of a major breakthrough with the immune checkpoint inhibitors which will probably overhaul the current algorithm.

In the **Pharmacotherapy** section the role of **immunotherapy in colorectal cancer** using different types of vaccines and antibody-based immunotherapy is examined. Although this has not yet reached clinical practice, it might in the very near future.

The **Oncocase** is about a metastatic **mixed adenoneuroendocrine carcinoma (MANEC) of the colon**, a rare entity that was very successfully treated and subjected to a detailed molecular dissection, shedding light on the pathogenesis.

The **Oncothesis** is about response predictors in **clear cell renal cell carcinoma** treated with anti-vascular endothelial growth factor-targeted therapy revealing major outcome predictors.

The **Congress News** section covers the **2014 SIOG** and highlights from the **2014 SABCS conferences**. There are also several **new oncology reimbursements** in Belgium.

You are also cordially invited to the **2015 BSMO Symposium, March 6-7**,

Jacques De Grève  
*Editor-in-Chief*